134 related articles for article (PubMed ID: 38507877)
41. Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer.
Manabe T; Bivona TG
J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166243
[TBL] [Abstract][Full Text] [Related]
42. DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRAS
Chiou LW; Chan CH; Jhuang YL; Yang CY; Jeng YM
J Biomed Sci; 2023 Jun; 30(1):50. PubMed ID: 37386628
[TBL] [Abstract][Full Text] [Related]
43. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).
Parums DV
Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327
[TBL] [Abstract][Full Text] [Related]
44. Bioinformatics and Experimental Validation for Identifying Biomarkers Associated with AMG510 (Sotorasib) Resistance in KRAS
Lin P; Cheng W; Qi X; Zhang P; Xiong J; Li J
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338834
[TBL] [Abstract][Full Text] [Related]
45. KRAS G12C inhibition with sotorasib in metastatic colorectal cancer.
Severi C; Van Cutsem E
Ann Palliat Med; 2022 Aug; 11(8):2792-2795. PubMed ID: 35989651
[No Abstract] [Full Text] [Related]
46. Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer.
Kavgaci G; Dizdar O; Yalcin S
Anticancer Drugs; 2024 Jun; 35(5):459-461. PubMed ID: 38451823
[TBL] [Abstract][Full Text] [Related]
47. Sotorasib after immune checkpoint inhibitor administration induces hepatotoxicity. True, false or just another adverse effect of NSCLC treatment.
Zarogoulidis P; Matthaios D; Oikonomou P; Nikolaou C; Charalampidis C; Sardeli C
Cancer Treat Res Commun; 2023; 37():100757. PubMed ID: 37666686
[TBL] [Abstract][Full Text] [Related]
48. Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report.
Iska S; Alley EW
Case Rep Oncol; 2023; 16(1):177-181. PubMed ID: 37008835
[TBL] [Abstract][Full Text] [Related]
49. Validation of an LC-MS/MS method for the determination of sotorasib, a KRAS
Wong P; Akrami A; Houk B; Vuu I; James CA
Bioanalysis; 2022 Oct; 14(19):1281-1292. PubMed ID: 36473022
[No Abstract] [Full Text] [Related]
50. Successful Use of Sotorasib in a Patient With End-Stage Renal Disease on Dialysis With Metastatic Lung Adenocarcinoma: A Case Report.
Sproat MR; Hofherr ML; Devarakonda S
Clin Lung Cancer; 2022 Sep; 23(6):e339-e341. PubMed ID: 35643747
[No Abstract] [Full Text] [Related]
51. Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of
Padda SK; Aredo JV; Vali S; Singh NK; Vasista SM; Kumar A; Neal JW; Abbasi T; Wakelee HA
JCO Precis Oncol; 2021 Nov; 5():153-162. PubMed ID: 34994595
[TBL] [Abstract][Full Text] [Related]
52. Sotorasib versus Docetaxel for treatment of US and Chinese patients with advanced non-small-cell lung cancer with KRAS p.G12C-mutated: A cost-effectiveness analysis to inform drug pricing.
Jiang Y; Zhao M; Liu R; Zheng X
Medicine (Baltimore); 2023 Dec; 102(50):e36387. PubMed ID: 38115313
[TBL] [Abstract][Full Text] [Related]
53. Sotorasib: First Approved
De SK
Curr Med Chem; 2023; 30(9):1000-1002. PubMed ID: 36082871
[No Abstract] [Full Text] [Related]
54. Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS
Ernst SM; van Marion R; Atmodimedjo PN; de Jonge E; Mathijssen RHJ; Paats MS; de Bruijn P; Koolen SL; von der Thüsen JH; Aerts JGJV; van Schaik RHN; Dubbink HJ; Dingemans AC
J Thorac Oncol; 2024 Apr; ():. PubMed ID: 38615940
[TBL] [Abstract][Full Text] [Related]
55. KRAS-targeted therapy in the treatment of non-small cell lung cancer.
Yun J; Nakagawa R; Tham K
J Oncol Pharm Pract; 2023 Mar; 29(2):422-430. PubMed ID: 35938195
[TBL] [Abstract][Full Text] [Related]
56. KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges.
Moldvay J; Tímár J
Pathol Oncol Res; 2023; 29():1611580. PubMed ID: 38239281
[TBL] [Abstract][Full Text] [Related]
57. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated
Fakih MG; Salvatore L; Esaki T; Modest DP; Lopez-Bravo DP; Taieb J; Karamouzis MV; Ruiz-Garcia E; Kim TW; Kuboki Y; Meriggi F; Cunningham D; Yeh KH; Chan E; Chao J; Saportas Y; Tran Q; Cremolini C; Pietrantonio F
N Engl J Med; 2023 Dec; 389(23):2125-2139. PubMed ID: 37870968
[TBL] [Abstract][Full Text] [Related]
58. Brain Mural Cells Express CAR T-cell Target.
Cancer Discov; 2020 Dec; 10(12):1781-1782. PubMed ID: 33097477
[TBL] [Abstract][Full Text] [Related]
59. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
60. Mercapturate pathway metabolites of sotorasib, a covalent inhibitor of KRAS
Werner JA; Davies R; Wahlstrom J; Dahal UP; Jiang M; Stauber J; David B; Siska W; Thomas B; Ishida K; Humphreys WG; Lipford JR; Monticello TM
Toxicol Appl Pharmacol; 2021 Jul; 423():115578. PubMed ID: 34004237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
